Introduction

61
Autoimmunity is increasingly accepted as the origin or amplifier of heart failure (1). For 62 cardiomyopathies, preferentially for dilated cardiomyopathy (DCM) with idiopathic nature (as 63 recently for the US re-calculated prevalence of 1 in 250-400 individuals (2)) and that 64 secondarily to non-ischemic causes, e.g. infectious diseases such as myocarditis, several 65 autoantibodies directed against cardiac antigens were discussed for breaking self-tolerance, 66 leading to autoimmunity causing or supporting the disease pathogenesis (3). Among the 67 autoantibodies, there are "classic" ones which induce immune responses, resulting in the 68 destruction of affected tissues, whereby autoantibodies directed against contractile elements 69 such as anti-myosin and anti-troponin autoantibodies are particularly important (4,5).
70
Starting in the 1970s, the classic autoantibodies were supplemented by an additional class of 71 autoantibodies that bind to G-protein coupled receptors (GPCR-AAB). After receptor binding,
72
GPCR-AAB, in the majority of cases, agonistically activate their related receptors in a similar 73 way to the physiological agonists; therefore GPCR-AAB were called "functional 74 autoantibodies". However, mechanisms for the prevention of over-boarding receptor 75 stimulation such as receptor down-regulation and desensitization, which are well known with 76 physiological agonists, are lacking for GPCR-AAB. Consequently, GPCR-AAB are discussed 77 as disease drivers as repeatedly summarized in (6-9).
78
With the finding of GPCR-AAB such as directed against the β1-adrenergic receptor (β1-AAB) 79 and muscarinic receptor 2 (M2-AAB) (10,11) in patients with DCM of non-ischemic reasons, 80 an autoimmune background of specifically associated with GPCR-AAB emerged. In contrast, 81 patients with ischemic cardiomyopathy and healthy individuals carry GPCR-AAB only in very 82 small amounts or these are completely absent (9).
83
GPCR-AAB directed against the β1-adrenerdic receptor are seen in 70-80% of patients with 84 non-ischemic DCM (6-9).
85
In a distinct group of these patients, preferentially those suffering from arrhythmia, M2-AAB 86 were additionally found with a prevalence of up to 40% (6). Among all heart specific classical 87 and functional autoantibodies, however, the strongest pathogenicity has been demonstrated 88 related to human DCM for β1-AAB, so that they are increasingly accepted as pathogenic 89 drivers and treatment targets, as summarized in (6-9).
90
Three lines of investigation have proposed the concept of β1-AAB dependent autoimmunity in 91 the pathogenesis of human DCM; first, experiments using myocardial cells to demonstrate the 92 cardio-pathogenic effects of β1-AAB at the cellular and subcellular levels; second, animal 93 experiments where rodents were immunized for β1-AAB generation to demonstrate their 94 cardio-pathogenic effects; and third, and most impressive, clinical trials demonstrating the 95 benefit to DCM patients when specifically their β1-AAB were removed by immunoadsorption 96 (IA) (12, 13) . This treatment option is now increasingly accepted for DCM patients positive for 97 β1-AAB. However, to overcome the problems of IA resulting from costs, logistics and patient 98 burden, drug-associated treatment concepts for the in vivo neutralization of β1-AAB come 99 increasingly to the fore (14,15). Unfortunately, to manifest and extend the knowledge about 100 functional autoantibodies in human DCM in general and specifically of β1-AAB and even more 101 to prove related treatment concepts in pre-clinical studies, there is a lack of animal models that 102 are more related to human DCM than the rather artificial rodent immunization models (16,17).
103
Although, there are also rodent models with naturally occurring DCM and transgenic mouse 104 lines that were engineered for cardiomyopathy development. There are even mice crossed 105 from transgenic and knockout ones which develop a "so-called" autoimmune cardiomyopathy (18, 19) . However, there is currently no evidence that such rodents may be suitable to eliminate 107 the lack of models for analyzing the pathogenic role of functional autoantibody associated 108 autoimmunity in human DCM and specifically the role of β1-AAB and M2-AAB as a driver and 109 treatment target. 129 Here, we demonstrate for the first time that DP frequently carry β1-AAB that could act as a 130 pathogenic driver in the pathogenesis of cardiomyopathy in a similar way to β1-AAB in human 131 DCM. Therefore, we suggest that DP could be a suitable model for basic investigation to 132 determine the relationship between β1-AAB-associated autoimmunity and cardiomyopathy, 133 and even more importantly, to prove treatment concepts to counteract β1-AAB in vivo.
106
135
Materials and Methods
136
The study was conducted in accordance with the German animal welfare law. The study 137 protocol was approved by the "Regierung von Oberbayern". DP were enrolled based on owner 138 study agreement. 
188
GmbH, Berlin-Buch, Germany). Then, this mixture was added to the Bioassay for GPCR-AAB 189 measurement. In the case of finding the β1-AAB epitope, the activity was measured as 190 described above in the presence of atropine; for M2-AAB, the bioassay was performed in the 191 presence of bisoprolol. Among the 9 dogs which were healthy at the time of enrolment (DoCM T0) but progressed to 282 DoCM, one of these animals was negative for β1-AAB at enrolment and remained negative 283 despite progressing to DoCM diagnosed by VPC (DoCM T1) and later than by VPC combined 284 with pathologic echocardiography (DoCM T2). The other 8 dogs were β1-AAB positive at 285 enrolment. In parallel to the cardiomyopathy development, the β1-AAB levels increased from 286 T0 to T1 in all DP (p<0.05) and in β1-AAB positive DP at study enrolment (p<0.02), from T1 287 to T2 in all DP (n.s) and in β1-AAB positive DP at study enrolment (p<0.02), as well as from 288 T0 to T2 in all DP (p<0.05), and in β1-AAB positive DP at study enrolment (p<0.02). A further 289 rise in β1-AAB from T1 to T2 was demonstrated for seven DP. In the one dog that showed a 290 decrease in the β1-AAB level from T1 to T2, the β1-AAB level remained clearly in the 291 pathological range (Figure 1 ).
292
In the comparison of dogs who were free of DoCM for the whole study period with those without 293 the signs of DoCM at enrolment but who progressed to DoCM, a significantly higher proportion 294 of β1-AAB positivity (p=0.044) was calculated for the last animals. 
378
The majority of dogs (93.5%) do not survive 2 years after being diagnosed with DoCM (42), 379 which is in agreement with our findings. Despite optimal treatment, the survival of the dogs is 380 about 130 days (median) after entering the overt stage (43).
381
Almost 30 years ago, Smucker et al. (25) suggested that DP should be used as a model for 382 human DCM. Subsequently, DP with dilated cardiomyopathy were announced as "… 383
remain(ing) (an) untapped resources to investigate both mechanisms of arrhythmias and
384 pharmacodynamics of anti-arrhythmics" (21).
385
However, DP as a DCM model did not gain widespread acceptance in basic research and also 386 not in pre-clinical studies for the testing of human drugs.
387
For the pathogenesis of DoCM, a genetic background is discussed and a autosomal dominant 388 inheritance was proposed (41) 
407
In our study cohort, DP with DoCM showed a prevalence of β1-AAB of about 70%, comparable 408 as is in human DCM (6). Furthermore, non-surviving dogs were significantly more often positive 409 for β1-AAB than survivors, which clearly agrees the findings with patients with human DCM 410 studies (48-50).
411
Interestingly, the dogs of our control group also carried β1-AAB (about 60% 
438
However, β1-AAB directed against the second extracellular receptor loop were sometimes (52) 439 but not always (34) accused of being the determining cause of DCM.
440
As for β1-AAB of DCM patients described in (14, 37, 39) , the β1-AAB activity of Doberman 
460
From our point of view, this is all the more important since, firstly, none of the small animal 461 models used for the modelling of human DCM to date develop functional autoantibodies and, 462 secondly, the functional autoantibodies found in the immunization models seem, based on 463 ELISA experiments (56) to differ from the human autoantibodies in quality and quantity.
464
We agree that a large animal model such as the DP is a priori cost-intensive and there are 465 strong requirements based on "World Medical Statement on Animal Use in Biomedical
466
Research" to respect the welfare of animals in general and specifically of large animals such 467 as DP used for research. However, a study design such as used for the present study with 468 enrolment of client-owned purebred DP attending a veterinary-medical institution for routine 469 check-up, disease diagnostics or follow-up would strongly minimize the cost and guarantee 470 the DP's welfare. In addition, the DP of our study came from different breeding populations 471 throughout Europe and therefore has a greater genetic diversity than the DP from one litter or only a few and can therefore better reflect the pathogenic situation in human DCM with its 473 already mentioned very different genetic background.
474
Last but not least, we have learned that dog owners have a great willingness to participate with 475 their dogs in studies that test new treatment options, especially if it is expected that the 476 treatments can also be beneficial to their dog; always provided that a study design is chosen 477 that guarantees a minimal physiological and psychological impairment of the animals, which 478 was ensured in our study by non-invasive heart examination and only blood analysis.
480
Study limitations
481
Based on the diagnostic criteria for DoCM used in our study, the control group consisted of 482 healthy animals and DP at stage 1 of DoCM. It is assumed that the dogs at this stage exhibit 483 genetic mutations that lead to myocardial alteration at the subcellular level without becoming 484 electrically or echocardiographically visible. We suspected that the β1-AAB-positive DP of the 485 control group were those at level 1 of the DoCM. In the future, a detailed characterization of 486 the DP with respect to a genetic predisposition is necessary to verify this speculation.
488 Conclusions
489
Doberman pinschers with cardiomyopathy presented with typical signs for autoimmunity, 490 preferentially with autoimmunity associated with autoantibodies directed against G-protein 491 coupled receptors, which is closely related to the autoimmunity found in patients with DCM.
492
This, together with the higher prevalence of cardiomyopathy in Doberman pinschers, the fast 493 disease progression and reaching the primary end point of death within around 4 months of 494 entering the severe stage of cardiomyopathy, presents an excellent basis to re-activate 495 Doberman pinschers as a model to study the basics of human DCM. This is specifically the 496 case for GPCR-AAB associated autoimmunity as a disease cause and as a model for pre-497 clinical studies in drug development aimed at counteracting this form of autoimmunity and 498 consequently DCM.
